Cat. #152087
MCF7/TAMR-7 Cell line
Cat. #: 152087
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Tumour line
£800.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne Lykkesfeldt
Institute: Danish Cancer Society, Denmark
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: MCF7/TAMR-7 Cell line
- Alternate name: MCF-7/TAMR-7; TAMR-7
- Cancer: Breast cancer
- Cancers detailed: Breast cancer;Tamoxifen resistant
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: MCF7 S0.5
- Organism: Human
- Gender: Female
- Tissue: Breast
- Disease: Cancer
- Model: Tumour line
- Conditional: Yes
- Description: MCF7/TAMR-7 cell line is a stable tamoxifen-resistant subline. The cell line has been established in tissue culture after long term treatment with 1uM tamoxifen. Tamoxifen (Nolvadex) is a widely used drug for hormone-dependent cancer. Tamoxifen resistance (either primary or acquired) makes oestrogen receptor-positive breast cancer much more difficult to treat. This cell line was produced as an adaptation of an original cell line (MCF7/S0.5), as a model cell system to study the effects of tamoxifen resistant cancer growth. MCF7/TAMR-7 cells are oestrogen receptor positive and progesterone receptor negative. Previous applications of this cell line include treatment with steroidal antiestrogens. MCF7/TAMR-7 enables identification of new hormone therapies and greater understanding of the signalling pathways/methods behind tamoxifen resistance.
- Application: Investigate signalling pathways involved in tamoxifen resistance
- Production details: The parental cell line for the MCF7/TAMR-7 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-7 has been established from a clone of cells that survived long term treatment with 1 uM tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 uM tamoxifen, which is lethal for the parental MCF7/S0.5 cell line.
- Recommended controls: MCF7-S0.5 parental line
- Cellosaurus id: 1D43
Target Details
- Target: Oestrogen receptor
Applications
- Application: Investigate signalling pathways involved in tamoxifen resistance
- Application notes: MCF7/TAMR-7 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-7 cells are growth inhibited by the pure antioestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-7 cell. The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment with tamoxifen was started in passage 351. Few colonies of cells survived the treatment and a...
Handling
- Format: Frozen
- Growth medium: Phenol red-free DMEM:Ham's F-12 containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 uM).
- Temperature: 37° C
- Atmosphere: 5% CO2
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
Related Tools
- Related tools: MCF7/S0.5 Cell Line
References
- Hole et al. 2015. Int J Oncol. 46(4):1481-1490. PMID: 25625755.
- Elias et al. 2015. Oncogene. 34(15):1919-1927. PMID: 24882577.
- Pedersen et al. 2014. Int J Oncol. 45(5):2167-2175. PMID: 25175082.
- Lundqvist et al. 2014. Steroids. 85:30-35. PMID: 24747771.
- Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
- Larsen et al. 2012. Int J Oncol. 41(5):1863-1870. PMID: 22961366.
- Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-179. PMID: 17061041.
- Berstein et al. 2003. Endocr Relat Cancer. 10(2):267-277. PMID: 12790788.
